José‐Ángel Hernández‐Rivas

Universidad Complutense de Madrid — Spain

Medicine · Health Sciences

50h-index9.0kcitations583works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(148), Lymphoma Diagnosis and Treatment(107), Multiple Myeloma Research and Treatments(94), Protein Degradation and Inhibitors(61), Chemokine receptors and signaling(54)

Publications578 total

Strengthening Radiation Therapy Access in Latin America Through SOLAR: A Collaborative Future
International Journal of Radiation Oncology*Biology*Physics·2025
Supplementary Figure 3 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Figure 8 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Figure 9 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Figure 1 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Figure 10 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Table 3 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Figure 3 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Table 1 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Figure 4 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Table 1 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Table 2 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Figure 5 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Data from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025· 1 citedOpen Access
Supplementary Figure 2 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Figure 7 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Table 5 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Table 3 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Table 2 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Figure 1 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
page 1 of 29Next →

Frequent Co-authors

Jesús F. San Miguel(16), Alberto Órfão(11), Josefina Galende(8), Bruno Paiva(7), María‐Belén Vídriales(7), Gema Mateo(7), Alfonso García de Coca(7), María‐Victoria Mateos(7), Raúl Córdoba(7), Ramón García‐Sánz(7), Abelardo Bárez(7), Anna Sureda(6), Marcos González(6), Norma C. Gutiérrez(5), Alejandro Martı́n(5), Juan José Lahuerta(5), Javier López‐Jiménez(5), Ozren Jakšić(5), Joaquín Martínez‐López(5), Júlia Almeida(5)